CLX Medical, Inc. Issues August 2008 Newsletter Highlighting Planned Acquisition of the ThyroTest(R) Rapid Screening Device

Newsletter Also Covers Additional Recent Announcements Regarding New Master Distributor for European Market and CEO Q&A

MURRIETA, CA–(EMWNews – August 18, 2008) – CLX Medical, Inc. (OTCBB: CLXN), which is

focused on the launch and distribution of unique medical diagnostic testing

products, today announced the release of the company’s August 2008 investor

newsletter, which highlights the company’s recent announcement of a letter

of intent with ThyroTec, LLC to acquire ThyroTest®, a rapid thyroid

stimulating hormone (TSH) screening device used for the detection of

hypothyroidism in adults, a common thyroid disease.

A PDF version of the August 2008 newsletter can be viewed on the company’s

corporate website at http://www.clxmedical.com/newsletters.php.

With the letter of intent announced, CLX will now proceed toward a

definitive agreement for the acquisition of ThyroTest®, which would be

positioned in a wholly owned subsidiary of CLX Medical. ThyroTest® is

FDA cleared and has also achieved CLIA waived status, so the test can be

administered in the more than 100,000 CLIA waived doctors’ offices in the

U.S., as well as in any non-waived laboratory.

In addition to the planned acquisition of ThyroTest®, the newsletter

reviews agreement with LETI Laboratories, a Barcelona-based

biopharmaceutical company that operates with exclusive distributors in

countries across Europe, to serve as the sole importer of CLX’s subsidiary

products into the European market. As Master Distributor for CLX products,

LETI Laboratories will provide product support and product packaging

control; coordinate sales to other European distributors; distribute the

company’s products in Spain and Portugal; act as the registered EU

representative for CE marked products; serve as the one point of entry for

CLX products into Europe; and assist with the development and

implementation of pricing structures.

In the place of a CEO Greeting, a CEO Question and Answer featuring Vera

Leonard that was recently posted to the CLX Medical website has been

included in the newsletter.

“The announcement of ThyroTest® as the targeted acquisition for CLX and

the selection of LETI Laboratories to serve as the sole importer of CLX’s

subsidiary products into the European market are both milestone events for

the company, and we are pleased to have the opportunity to review them in

our investor newsletter,” stated Ms. Leonard. “As important as these

announcements are, we expect additional significant events to follow, and

we hope that shareholders will continue to monitor the evolving story of

CLX Medical.”

To sign up to receive information by email directly from CLX Medical, Inc.

when new press releases, investor newsletters, SEC filings, or other

information is disclosed, please visit

http://www.clxinvestments.com/email.php.

About CLX Medical, Inc.

CLX Medical, Inc. (www.clxmedical.com) holds a 51% equity interest in

Zonda, Inc. (www.zondaincusa.com), which has developed several rapid point

of care tests for medical and non-medical markets, including a rapid test

for Chlamydia. CLX recently announced a letter of intent to acquire

ThyroTest®, a rapid thyroid stimulating hormone (TSH) screening device

used for the detection of hypothyroidism in adults, a common thyroid

disease. CLX Medical is focused on the successful worldwide distribution

of these and any additional products it may acquire or license.

All statements included in this release, including statements regarding

potential future plans and objectives of CLX Medical, Inc. are

forward-looking statements. Such statements are necessarily subject to

risks and uncertainties, some of which are significant in scope and nature

beyond CLX Medical’s control. There can be no assurance that such

statements will prove accurate. Actual results and future events could

differ materially from those anticipated in such statements depending on

many factors. Historical results are not necessarily indicative of future

performance.